Literature DB >> 3928488

Effects of a specific and long-acting renin inhibitor in the marmoset.

J M Wood, N Gulati, P Forgiarini, W Fuhrer, K G Hofbauer.   

Abstract

Inhibition of renin was induced in conscious marmosets with CGP 29 287, Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys (Boc)-OMe, a renin inhibitor with a prolonged duration of action. In vitro, CGP 29 287 is a potent inhibitor of primate plasma renin (inhibitory concentration, 50%: human = 1 X 10(-9) M; marmoset = 5 X 10(-9) M) and less potent against dog (2 X 10(-7) M) or rat (3 X 10(-5) M) plasma renin. CGP 29 287 is a weak inhibitor of other aspartic proteases such as porcine pepsin or bovine cathepsin D (inhibitory concentration, 50% = 4 X 10(-5) M). In furosemide-treated marmosets, CGP 29 287 lowered blood pressure and inhibited plasma renin activity during intravenous infusion and after intravenous bolus injection. The duration of action after intravenous injection was dose dependent and ranged from 1 hour after 0.1 mg/kg to more than 3 hours after 10 mg/kg. High doses of CGP 29 287 (100 mg/kg) were active after oral administration. In all experiments a close relation between inhibition of plasma renin activity and reduction of blood pressure was found. A maximum hypotensive response to CGP 29 287 was associated with complete inhibition of plasma renin activity, and the recovery of blood pressure was accompanied by recovery of plasma renin activity. The hypotensive effects of CGP 29 287 were smaller in untreated than in furosemide-treated marmosets. CGP 29 287 had no influence on blood pressure in marmosets after bilateral nephrectomy or after pretreatment with a converting enzyme inhibitor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928488     DOI: 10.1161/01.hyp.7.5.797

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Dynamic Ca2+ signalling in rat arterial smooth muscle cells under the control of local renin-angiotensin system.

Authors:  Y Asada; T Yamazawa; K Hirose; T Takasaka; M Iino
Journal:  J Physiol       Date:  1999-12-01       Impact factor: 5.182

2.  Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers.

Authors:  M de Gasparo; F Cumin; J Nussberger; T T Guyenne; J M Wood; J Menard
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

3.  Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

Authors:  Venkata V Pavan Kumar; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

Review 4.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

Review 5.  Renin inhibitors.

Authors:  W J Greenlee
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

6.  Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues.

Authors:  D I Friedman; G L Amidon
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

7.  Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.

Authors:  A H van den Meiracker; P J Admiraal; A J Man in 't Veld; F H Derkx; H J Ritsema van Eck; P Mulder; P van Brummelen; M A Schalekamp
Journal:  BMJ       Date:  1990-07-28

Review 8.  Renin inhibitors as possible antihypertensive agents.

Authors:  K G Hofbauer; J M Wood
Journal:  Klin Wochenschr       Date:  1988-09-15

9.  Estimation of regional metabolism and production of angiotensins in hypertensive subjects.

Authors:  M A Schalekamp; P J Admiraal; F H Derkx
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 10.  Renin inhibition.

Authors:  H D Kleinert
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.